This is a working overview of analytical standard, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-01-26. Anything still debated is marked as such rather than presented as settled.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Visual inspection is not sufficient for identity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water; stock solutions use organic solvent. |
| Storage | -20°C, desiccated, protected from light | Limits hydrolysis and photodegradation. |
| Analytical method | HPLC-UV/MS | Used for identity and purity assessment. |
| Synonyms | SR9009, Stenabolic | Naming varies by supplier. |
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
===== Adverse effects ===== Mild or moderate adverse events are common, expressing symptoms like nausea, facial flushing, headache, and sunburn. Unlike flibanserin, bremelanotide induces fewer side effects and is not affected nor develops severe complications with alcohol. However, the drug slows down gastric emptying, which can cause an impact on oral drug uptake and the subsequent drug effectiveness. As activation of MC1R gives rise to hyperpigmentation, treatment dosage is at a maximum of eight doses per month. Besides, to minimize the chances of cardiovascular complications, the prescribed daily dosage is at one dose.
the 2001 observation, that non-diabetic offspring of type 2 diabetics had increased arterial stiffness and neuropathy despite normal blood glucose levels, the 2008 observation, that non-diabetic first-degree relatives of diabetics had elevated enzyme levels associated with diabetic renal disease and nephropathy. the 2007 finding that non-diabetic family members of type 1 diabetics had increased risk for microvascular complications, such as diabetic retinopathy Some genes appear to provide protection against diabetic complications, as seen in a subset of long-term diabetes type 1 survivors without complications.
Outside Romania, public audiences in Western Europe initially projected generally idealistic notions of revolution on the country; the legacies of the French Revolution were fresh on people's minds in 1989 during its two-hundredth anniversary. However, as violence continued into 1990 and reports reached the West of mass casualties, this projected narrative shifted into a less sympathetic one characterized by disappointment in and suspicion of the revolution's direction.
Sources: en.wikipedia.org
Aldo Carl Leopold (December 18, 1919 – November 18, 2009) was an American academic and plant physiologist, son of Aldo Leopold, a noted ecologist. He is known for his research on soybeans which led to techniques allowing insulin to be dried and later processed into an inhalable insulin. Aldo Carl Leopold was born to Aldo Leopold, a noted ecologist and employee of the United States Forest Service, and Estella Leopold in Albuquerque, New Mexico as the 4th of 5 children.
A nuclide is a more general term than isotope, and refers to atoms that have any particular number of protons and neutrons. Stable nuclides are not radioactive and do not spontaneously undergo radioactive decay, so are more usually found in nature. Whereas unstable (i.e. radioactive) nuclides are not found in nature, unless there is a recent source of them, because they are shorter lived, and will spontaneously decay, in one or more steps, to more stable nuclides. For example, carbon-14 is unstable but is found in nature. Scientists use accelerators and nuclear reactors to produce radioactive nuclides. As a general trend, and among other factors, the neutron–proton ratio of a nuclide determines its stability. The value of this ratio for stable nuclides generally increases for larger nuclei with more protons and neutrons. Many unstable nuclides have neutron-proton ratios beyond the zone of stability. The time required to lose half of a quantity of a given nuclide through radioactive decays, the half-life, is a measure of how stable an isotope is. Nuclides can be visually represented on a table (Segré chart or table of nuclides) where the proton number is plotted against the neutron number.
Technetium, with atomic number Z = 43, is the lowest-numbered element in the periodic table for which all isotopes are radioactive. The second-lightest exclusively radioactive element, promethium, has atomic number 61. Atomic nuclei with an odd number of protons are less stable than those with even numbers, even when the total number of nucleons (protons + neutrons) is even, and odd numbered elements have fewer stable isotopes. The most stable radioactive isotopes are technetium-97 with a half-life of 4.21±0.16 million years and technetium-98 with 4.2±0.3 million years; current measurements of their half-lives give overlapping confidence intervals corresponding to one standard deviation and therefore do not allow a definite assignment of technetium's most stable isotope. The next most stable isotope is technetium-99, which has a half-life of 211,100 years. Thirty-four other radioisotopes have been characterized with mass numbers ranging from 86 to 122. Most of these have half-lives that are less than an hour, the exceptions being technetium-93 (2.75 hours), technetium-94 (4.88 hours), technetium-95 (19.26 hours), and technetium-96 (4.28 days). The primary decay mode for isotopes lighter than technetium-98 (98Tc) is electron capture, producing molybdenum (Z = 42). For technetium-98 and heavier isotopes, the primary mode is beta emission (the emission of an electron or positron), producing ruthenium (Z = 44), with the exception that technetium-98 and technetium-100 can decay both by beta emission and electron capture.
Insulin degludec/insulin aspart, sold under the brand name Ryzodeg, is a fixed-dose combination medication for the treatment of diabetes mellitus. It contains insulin degludec and insulin aspart. It is given as an injection under the skin in the abdominal wall (at the front of the waist), upper arm or thigh. The most frequently reported side effect is hypoglycemia (low blood glucose levels). It was approved for medical use in the European Union in January 2013, and in Australia in November 2017.
Sources: en.wikipedia.org
Liquid chromatography with mass spectrometry is a common approach. Ultraviolet detection and nuclear magnetic resonance can support identification when suitable standards are available.
The solid is generally kept cold, dry, and protected from light. Solutions are often frozen in single-use aliquots to reduce repeated freeze-thaw cycles.
It indicates a material sold for laboratory study, not for human use. The label does not guarantee pharmaceutical purity, sterility, or regulatory approval.
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.